AACR 2023 | Molecular determinants of KRAS G12C inhibitor efficacy in advanced NSCLC

Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of research elucidating the molecular determinants of KRAS G12C inhibitor efficacy in advanced non-small cell lung cancer (NSCLC). Genomic data of patients receiving a KRAS G12C inhibitor were analyzed and co-mutations in KEAP1, SMARCA4 and CDKN2A/2B were found to worsen outcomes in patients. Tailoring of treatment regimens should, thus, take into account the co-mutation status of the tumor. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.